{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:31Z","timestamp":1793948431853,"version":"4.8.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00210-025-04257-x","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:00:43Z","timestamp":1747202443000},"page":"13647-13665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Beyond obesity: lean metabolic dysfunction-associated steatohepatitis from unveiling molecular pathogenesis to therapeutic advancement"],"prefix":"10.1007","volume":"398","author":[{"given":"Indrajit","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep Kumar","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampriti","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teeshyo","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya","family":"Sreedhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somasundaram","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"4257_CR1","doi-asserted-by":"publisher","unstructured":"Abdelmoneim D, El-Adl M, El-Sayed G, El-Sherbini ES (2021) Protective effect of fenofibrate against high-fat\u2013high-fructose diet induced non-obese NAFLD in rats.\u00a0Fundam Clin Pharmacol\u00a035(2):379\u2013388. https:\/\/doi.org\/10.1111\/fcp.12597","DOI":"10.1111\/fcp.12597"},{"key":"4257_CR2","doi-asserted-by":"publisher","unstructured":"Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N (2018) Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease. Pharmaceuticals (Basel) 11(4). https:\/\/doi.org\/10.3390\/ph11040104","DOI":"10.3390\/ph11040104"},{"key":"4257_CR3","doi-asserted-by":"crossref","unstructured":"Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak NJP (2018) Obeticholic acid: a new era in the treatment of nonalcoholic fatty liver disease. 11(4):104","DOI":"10.3390\/ph11040104"},{"key":"4257_CR4","doi-asserted-by":"publisher","unstructured":"Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, . . . Dewey FE (2018) A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 378(12):1096\u20131106. https:\/\/doi.org\/10.1056\/NEJMoa1712191","DOI":"10.1056\/NEJMoa1712191"},{"key":"4257_CR5","doi-asserted-by":"crossref","unstructured":"Ajoolabady A, Kaplowitz N, Lebeaupin C, Kroemer G, Kaufman RJ, Malhi H, Ren JJH (2023) Endoplasmic reticulum stress in liver diseases. 77(2):619-639","DOI":"10.1002\/hep.32562"},{"key":"4257_CR6","doi-asserted-by":"publisher","unstructured":"Alexander H, Falk R, Utz S, Felix D, Aladdin AD, Hermann K, . . . Michael A (2025) Comparison of different liver fibrosis scores following sleeve gastrectomy. Langenbeck's Arch Surg 410(1):29. https:\/\/doi.org\/10.1007\/s00423-024-03569-5","DOI":"10.1007\/s00423-024-03569-5"},{"key":"4257_CR7","doi-asserted-by":"publisher","unstructured":"Alharthi J, Pan Z, Gloss BS, McLeod D, Weltman M, George J, Eslam M (2023) Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metab \u2013 Clin Exp 144. https:\/\/doi.org\/10.1016\/j.metabol.2023.155583","DOI":"10.1016\/j.metabol.2023.155583"},{"issue":"1","key":"4257_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.17292","volume":"57","author":"M Amangurbanova","year":"2023","unstructured":"Amangurbanova M, Huang DQ, Loomba R (2023) Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 57(1):37\u201351. https:\/\/doi.org\/10.1111\/apt.17292","journal-title":"Aliment Pharmacol Ther"},{"key":"4257_CR9","doi-asserted-by":"publisher","unstructured":"Amirkalali B, Khoonsari M, Sohrabi MR, Ajdarkosh H, Motamed N, Maadi M, . . . Zamani F (2021) Relationship between dietary macronutrient composition and non-alcoholic fatty liver disease in lean and non-lean populations: a cross-sectional study. Public Health Nutr 24(18):6178\u20136190. https:\/\/doi.org\/10.1017\/s1368980021001762","DOI":"10.1017\/s1368980021001762"},{"key":"4257_CR10","doi-asserted-by":"crossref","unstructured":"Anastasia I, Ilacqua N, Raimondi A, Lemieux P, Ghandehari-Alavijeh R, Faure G, . . . Valle GJCR (2021) Mitochondria-rough-ER contacts in the liver regulate systemic lipid homeostasis. 34(11)","DOI":"10.1016\/j.celrep.2021.108873"},{"issue":"6","key":"4257_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R (2022) Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 76(6):1362\u20131378. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.026","journal-title":"J Hepatol"},{"key":"4257_CR12","doi-asserted-by":"crossref","unstructured":"Anushiravani A, Khamirani HJ, Mohamadkhani A, Mani A, Dianatpour M, Malekzadeh RJAoIm (2023) A form of metabolic-associated fatty liver disease associated with a novel LIPA variant. 26(2):86","DOI":"10.34172\/aim.2023.14"},{"key":"4257_CR13","doi-asserted-by":"publisher","unstructured":"Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, . . . Sanyal AJ (2016) A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 65(3):579\u2013588. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.005","DOI":"10.1016\/j.jhep.2016.05.005"},{"key":"4257_CR14","doi-asserted-by":"crossref","unstructured":"Baiceanu A, Mesdom P, Lagouge M, Foufelle FJNRE (2016) Endoplasmic reticulum proteostasis in hepatic steatosis. 12(12):710-722","DOI":"10.1038\/nrendo.2016.124"},{"issue":"5","key":"4257_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jceh.2019.02.001","volume":"9","author":"G Bale","year":"2019","unstructured":"Bale G, Vishnubhotla RV, Mitnala S, Sharma M, Padaki RN, Pawar SC, Duvvur RN (2019) Whole-exome sequencing identifies a variant in phosphatidylethanolamine N-methyltransferase gene to be associated with lean-nonalcoholic fatty liver disease. J Clin Exp Hepatol 9(5):561\u2013568. https:\/\/doi.org\/10.1016\/j.jceh.2019.02.001","journal-title":"J Clin Exp Hepatol"},{"key":"4257_CR16","unstructured":"Basaranoglu M, Basaranoglu G, Bugianesi E\u00a0(2015)\u00a0Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. Hepatobiliary Surg Nutr 4(2):109"},{"issue":"2","key":"4257_CR17","doi-asserted-by":"publisher","first-page":"G211","DOI":"10.1152\/ajpgi.00040.2019","volume":"318","author":"DA Breuer","year":"2020","unstructured":"Breuer DA, Pacheco MC, Washington MK, Montgomery SA, Hasty AH, Kennedy AJ (2020) CD8(+) T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 318(2):G211-g224. https:\/\/doi.org\/10.1152\/ajpgi.00040.2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4257_CR18","doi-asserted-by":"publisher","unstructured":"Burelle C, Clapatiuc V, Desch\u00eanes S, Cuillerier A, De Loof M, Higgins M-\u00c8, . . . Ruiz M (2024) A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis. Commun Biol 7(1):356. https:\/\/doi.org\/10.1038\/s42003-024-06035-6","DOI":"10.1038\/s42003-024-06035-6"},{"key":"4257_CR19","doi-asserted-by":"publisher","unstructured":"Buzova D, Maugeri A, Liguori A, Napodano C, Lo Re O, Oben J, . . . Vinciguerra M (2020) Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin Epigenet 12(1):126. https:\/\/doi.org\/10.1186\/s13148-020-00917-2","DOI":"10.1186\/s13148-020-00917-2"},{"key":"4257_CR20","doi-asserted-by":"crossref","unstructured":"Chambel SS, Santos-Gon\u00e7alves A, Duarte TLJBri (2015) The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism.\u00a0Biomed Res Int\u00a02015(1):597134","DOI":"10.1155\/2015\/597134"},{"issue":"Suppl","key":"4257_CR21","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.3350\/cmh.2022.0350","volume":"29","author":"W-K Chan","year":"2023","unstructured":"Chan W-K (2023) Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol 29(Suppl):S58\u2013S67. https:\/\/doi.org\/10.3350\/cmh.2022.0350","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4257_CR22","doi-asserted-by":"publisher","first-page":"7706","DOI":"10.1038\/srep07706","volume":"5","author":"S Chatterjee","year":"2015","unstructured":"Chatterjee S, Majumder A, Ray S (2015) Observational study of effects of saroglitazar on glycaemic and lipid parameters on indian patients with type 2 diabetes. Sci Rep 5(1):7706. https:\/\/doi.org\/10.1038\/srep07706","journal-title":"Sci Rep"},{"key":"4257_CR23","doi-asserted-by":"publisher","unstructured":"Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, . . . Eslam M (2020) Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. 71(4):1213\u20131227. https:\/\/doi.org\/10.1002\/hep.30908","DOI":"10.1002\/hep.30908"},{"key":"4257_CR24","doi-asserted-by":"publisher","unstructured":"Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, . . . Eslam M (2020) Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology 71(4):1213\u20131227. https:\/\/doi.org\/10.1002\/hep.30908","DOI":"10.1002\/hep.30908"},{"key":"4257_CR25","doi-asserted-by":"crossref","unstructured":"Chen M, Cao Y, Ji G, Zhang LJFiE (2023) Lean nonalcoholic fatty liver disease and sarcopenia.\u00a0Front Endocrinol\u00a014:1217249","DOI":"10.3389\/fendo.2023.1217249"},{"issue":"12","key":"4257_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/14728222.2021.2018418","volume":"25","author":"A Cherubini","year":"2021","unstructured":"Cherubini A, Casirati E, Tomasi M, Valenti L (2021) PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 25(12):1033\u20131043. https:\/\/doi.org\/10.1080\/14728222.2021.2018418","journal-title":"Expert Opin Ther Targets"},{"key":"4257_CR27","doi-asserted-by":"publisher","unstructured":"Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag, A, . . . George J (2019) ADAPT: an algorithm incorporating PRO\u2010C3 accurately identifies patients with NAFLD and advanced fibrosis. 69(3):1075\u20131086. https:\/\/doi.org\/10.1002\/hep.30163","DOI":"10.1002\/hep.30163"},{"issue":"1","key":"4257_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-022-00814-z","volume":"14","author":"JK DiStefano","year":"2022","unstructured":"DiStefano JK, Gerhard GS (2022) NAFLD in normal weight individuals. Diabetol Metab Syndr 14(1):45. https:\/\/doi.org\/10.1186\/s13098-022-00814-z","journal-title":"Diabetol Metab Syndr"},{"key":"4257_CR29","doi-asserted-by":"crossref","unstructured":"Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo MJFii (2022) Association of inflammatory cytokines with non-alcoholic fatty liver disease. 13:880298","DOI":"10.3389\/fimmu.2022.880298"},{"key":"4257_CR30","doi-asserted-by":"publisher","unstructured":"Duarte SMB, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada L, . . . Oliveira CP (2018) Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a\u00a0prospective pilot study. Nutr Metab Cardiovasc Dis 28(4):369\u2013384. https:\/\/doi.org\/10.1016\/j.numecd.2017.10.014","DOI":"10.1016\/j.numecd.2017.10.014"},{"key":"4257_CR31","doi-asserted-by":"crossref","unstructured":"Eslam M, Valenti L, Romeo SJJoh (2018) Genetics and epigenetics of NAFLD and NASH: Clinical impact. 68(2):268\u2013279","DOI":"10.1016\/j.jhep.2017.09.003"},{"key":"4257_CR32","doi-asserted-by":"publisher","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, . . . George J (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 73(1):202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"4257_CR33","doi-asserted-by":"publisher","unstructured":"Farrell GC, Mridha AR, Yeh MM, Arsov T, Van Rooyen DM, Brooling J, . . . Larter CZ (2014) Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype. 34(7):1084\u20131093. https:\/\/doi.org\/10.1111\/liv.12335","DOI":"10.1111\/liv.12335"},{"key":"4257_CR34","doi-asserted-by":"crossref","unstructured":"Flessa CM, Kyrou I, Nasiri\u2010Ansari N, Kaltsas G, Kassi E, Randeva HSJJoCB (2022) Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD\/MAFLD). 123(10):1585\u20131606","DOI":"10.1002\/jcb.30247"},{"key":"4257_CR35","doi-asserted-by":"crossref","unstructured":"Gawrieh S, Chalasani NJCild (2018) Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.\u00a0Clin Liver Dis 22(1):189\u2013199","DOI":"10.1016\/j.cld.2017.08.013"},{"key":"4257_CR36","doi-asserted-by":"crossref","unstructured":"Giallongo S, Lo Re O, Lochmanov\u00e1 G, Parca L, Petrizzelli F, Zdr\u00e1hal Z, . . . Vinciguerra M (2021) Phosphorylation within intrinsic disordered region discriminates histone variant macroH2A1 splicing isoforms\u2014macroH2A1.1 and macroH2A1.2. 10(7):659","DOI":"10.3390\/biology10070659"},{"key":"4257_CR37","doi-asserted-by":"publisher","unstructured":"Gijbels A, Trouwborst I, Jardon KM, Hul GB, Siebelink E, Bowser SM, . . . Blaak EE (2021) The PERSonalized Glucose Optimization Through Nutritional Intervention (PERSON) study: rationale, design and preliminary screening results. 8. https:\/\/doi.org\/10.3389\/fnut.2021.694568","DOI":"10.3389\/fnut.2021.694568"},{"issue":"10","key":"4257_CR38","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R (2023) Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 21(10):2496-2507.e2495. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4257_CR39","doi-asserted-by":"publisher","unstructured":"Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, . . . Dombrowicz D (2019) Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution. Nat Metab 1(6):604\u2013614. https:\/\/doi.org\/10.1038\/s42255-019-0076-1","DOI":"10.1038\/s42255-019-0076-1"},{"key":"4257_CR40","doi-asserted-by":"publisher","unstructured":"Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, . . . Farrell GC (2018) Mouse models of non-alcoholic steatohepatitis: a reflection on recent literature. 33(7):1312\u20131320. https:\/\/doi.org\/10.1111\/jgh.14122","DOI":"10.1111\/jgh.14122"},{"key":"4257_CR41","doi-asserted-by":"publisher","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, . . . Haupt A (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43(6):1352\u20131355. https:\/\/doi.org\/10.2337\/dc19-1892 %J Diabetes Care","DOI":"10.2337\/dc19-1892"},{"key":"4257_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-017-0215-y","volume":"18","author":"B He","year":"2017","unstructured":"He B, Wu L, Xie W, Shao Y, Jiang J, Zhao Z, Cui DJBi, (2017) The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol 18:1\u20139","journal-title":"BMC Immunol"},{"key":"4257_CR43","doi-asserted-by":"crossref","unstructured":"Heda R, Yazawa M, Shi M, Bhaskaran M, Aloor FZ, Thuluvath PJ, Satapathy SKJWjog (2021) Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. 27(17):1864","DOI":"10.3748\/wjg.v27.i17.1864"},{"key":"4257_CR44","doi-asserted-by":"publisher","unstructured":"Helsley RN, Varadharajan V, Brown AL, Gromovsky AD, Schugar, RC, Ramachandiran I, . . . Brown JM (2019) Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. Elife 8. https:\/\/doi.org\/10.7554\/eLife.49882","DOI":"10.7554\/eLife.49882"},{"issue":"6","key":"4257_CR45","doi-asserted-by":"publisher","first-page":"906","DOI":"10.4158\/EP.17.6.906","volume":"17","author":"RR Henry","year":"2011","unstructured":"Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley REJEP (2011) Efficacy of anti hyperglycemic therapies and the influence of baseline hemoglobin A1C: a meta-analysis of the liraglutide development program. Endorine Practice 17(6):906\u2013913","journal-title":"Endorine Practice"},{"key":"4257_CR46","doi-asserted-by":"crossref","unstructured":"Hernansanz-Agust\u00edn P, Enr\u00edquez JAJA (2021) Generation of reactive oxygen species by mitochondria. 10(3):415","DOI":"10.3390\/antiox10030415"},{"issue":"1","key":"4257_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/dneu.22031","volume":"73","author":"D Heydet","year":"2013","unstructured":"Heydet D, Chen LX, Larter CZ, Inglis C, Silverman MA, Farrell GC, Leroux MR (2013) A truncating mutation of Alms1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol 73(1):1\u201313. https:\/\/doi.org\/10.1002\/dneu.22031","journal-title":"Dev Neurobiol"},{"key":"4257_CR48","doi-asserted-by":"publisher","unstructured":"Huang X, Yao Y, Hou X, Wei L, Rao Y, Su Y, . . . Chen Y (2022) Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-\u03baB signaling pathway. Cell Mol Gastroenterol Hepatol 14(1):1\u201326. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.03.006","DOI":"10.1016\/j.jcmgh.2022.03.006"},{"issue":"4","key":"4257_CR49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/iep.12240","volume":"98","author":"A Ikawa-Yoshida","year":"2017","unstructured":"Ikawa-Yoshida A, Matsuo S, Kato A, Ohmori Y, Higashida A, Kaneko E, Matsumoto M (2017) Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol 98(4):221\u2013233. https:\/\/doi.org\/10.1111\/iep.12240","journal-title":"Int J Exp Pathol"},{"key":"4257_CR50","doi-asserted-by":"crossref","unstructured":"Ioannidou D, Makri ES, Polyzos SA, Ntenti C, Agapakis D, Germanidis G, Goulas AJEoM (2023) An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia. 4(1):16\u201322","DOI":"10.37349\/emed.2023.00121"},{"key":"4257_CR51","doi-asserted-by":"publisher","unstructured":"Johnson SM, Bao H, McMahon CE, Chen Y, Burr SD, Anderson AM, . . . Liu J (2024) PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. Nat Commun 15(1):4847. https:\/\/doi.org\/10.1038\/s41467-024-49224-x","DOI":"10.1038\/s41467-024-49224-x"},{"key":"4257_CR52","doi-asserted-by":"crossref","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado IJIjoer, health (2021) Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors.\u00a0Int J Environ Res Public Health\u00a018(10):5227","DOI":"10.3390\/ijerph18105227"},{"issue":"11","key":"4257_CR53","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","volume":"13","author":"MA Kalas","year":"2021","unstructured":"Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S (2021) Abnormal liver enzymes: a review for clinicians. World J Hepatol 13(11):1688\u20131698. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1688","journal-title":"World J Hepatol"},{"key":"4257_CR54","doi-asserted-by":"publisher","unstructured":"Kim KE, Jung Y, Min S, Nam M, Heo RW, Jeon BT, . . . Hwang GS (2016) Caloric restriction of db\/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism. Sci Rep 6:30111. https:\/\/doi.org\/10.1038\/srep30111","DOI":"10.1038\/srep30111"},{"key":"4257_CR55","doi-asserted-by":"publisher","unstructured":"Kim Y, Han E, Lee JS, Lee HW, Kim BK, Kim MK, . . . Kim SU (2022) Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver 16(2):290\u2013299. https:\/\/doi.org\/10.5009\/gnl210084","DOI":"10.5009\/gnl210084"},{"key":"4257_CR56","doi-asserted-by":"publisher","unstructured":"Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, . . . Baker LH (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306(14):1549\u20131556. https:\/\/doi.org\/10.1001\/jama.2011.1437 %J JAMA","DOI":"10.1001\/jama.2011.1437"},{"key":"4257_CR57","doi-asserted-by":"crossref","unstructured":"Korbecki J, Bosiacki M, Kupnicka P, Barczak K, Zi\u0119tek P, Chlubek D, Baranowska-Bosiacka IJIJoMS (2024) Biochemistry and diseases related to the interconversion of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. 25(19):10745","DOI":"10.3390\/ijms251910745"},{"key":"4257_CR58","doi-asserted-by":"publisher","unstructured":"Kostadinova R, Str\u00f6bel S, Chen L, Fiaschetti\u2011Egli K, Gadient J, Pawlowska A, . . . Petitjean M (2024) Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. Sci Rep 14(1):5885. https:\/\/doi.org\/10.1038\/s41598-024-55438-2","DOI":"10.1038\/s41598-024-55438-2"},{"key":"4257_CR59","doi-asserted-by":"publisher","unstructured":"Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybj\u00e6rg-Hansen A, . . . Cohen JC (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46(4):352\u2013356. https:\/\/doi.org\/10.1038\/ng.2901","DOI":"10.1038\/ng.2901"},{"key":"4257_CR60","doi-asserted-by":"publisher","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, . . . Mithal A (2018) Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41(8):1801\u20131808. https:\/\/doi.org\/10.2337\/dc18-0165 %J Diabetes Care","DOI":"10.2337\/dc18-0165"},{"key":"4257_CR61","doi-asserted-by":"crossref","unstructured":"Kuchay MS, Mart\u00ednez-Montoro JI, Choudhary NS, Fern\u00e1ndez-Garc\u00eda JC, Ramos-Molina BJB (2021) Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. 9(10):1346","DOI":"10.3390\/biomedicines9101346"},{"key":"4257_CR62","unstructured":"Kumar H, Chaudhary A, Singh A, Sukhija N, Panwar A, Saravanan K, . . . Panigrahi MJJEZS (2020) A review on epigenetics: manifestations, modifications, methods & challenges. 8(4):01\u201306"},{"issue":"3","key":"4257_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jhep.2008.03.026","volume":"49","author":"CZ Larter","year":"2008","unstructured":"Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC (2008) MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 49(3):407\u2013416. https:\/\/doi.org\/10.1016\/j.jhep.2008.03.026","journal-title":"J Hepatol"},{"key":"4257_CR64","doi-asserted-by":"crossref","unstructured":"Lee SM, Muratalla J, Sierra-Cruz M, Cordoba-Chacon J\u00a0(2023) Role of hepatic peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease.\u00a0J Endocrinol 257(1)","DOI":"10.1530\/JOE-22-0155"},{"key":"4257_CR65","doi-asserted-by":"crossref","unstructured":"Li L, Fu J, Liu D, Sun J, Hou Y, Chen C, . . . Zhao RJRb (2020) Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPAR\u03b3 expression. 30:101412","DOI":"10.1016\/j.redox.2019.101412"},{"key":"4257_CR66","doi-asserted-by":"publisher","unstructured":"Li L, Zeng X, Liu Z, Chen X, Li L, Luo R, . . . Chen Y (2021) Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. J Cell Mol Med 25(6):2976\u20132993. https:\/\/doi.org\/10.1111\/jcmm.16338","DOI":"10.1111\/jcmm.16338"},{"key":"4257_CR67","doi-asserted-by":"crossref","unstructured":"Li L, Zeng X, Liu Z, Chen X, Li L, Luo R, . . . medicine m (2021) Mesenchymal stromal cells protect hepatocytes from lipotoxicity through alleviation of endoplasmic reticulum stress by restoring SERCA activity. 25(6):2976\u20132993.","DOI":"10.1111\/jcmm.16338"},{"key":"4257_CR68","doi-asserted-by":"crossref","unstructured":"Li J, Xin Y, Li J, Chen H, Li HJA, Disease (2023) Phosphatidylethanolamine N-methyltransferase: from functions to diseases. 14(3):879","DOI":"10.14336\/AD.2022.1025"},{"key":"4257_CR69","doi-asserted-by":"crossref","unstructured":"Li A, Wang R, Zhao Y, Zhao P, Yang JJM (2024) Crosstalk between epigenetics and metabolic reprogramming in metabolic dysfunction-associated steatotic liver disease-induced hepatocellular carcinoma: a new sight. 14(6):325","DOI":"10.3390\/metabo14060325"},{"key":"4257_CR70","doi-asserted-by":"publisher","unstructured":"Li L, Shu X, Yi Y, Wang C, Li J, Ding Y, . . . Chang Y (2024) Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003\u20132018. Lipids Health Dis 23(1):127. https:\/\/doi.org\/10.1186\/s12944-024-02082-4","DOI":"10.1186\/s12944-024-02082-4"},{"issue":"19","key":"4257_CR71","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1021\/acs.accounts.1c00463","volume":"54","author":"X Li","year":"2021","unstructured":"Li X, Li XD (2021) Integrative chemical biology approaches to deciphering the histone code: a problem-driven journey. Acc Chem Res 54(19):3734\u20133747. https:\/\/doi.org\/10.1021\/acs.accounts.1c00463","journal-title":"Acc Chem Res"},{"issue":"1","key":"4257_CR72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12929-023-00975-7","volume":"30","author":"L Liu","year":"2023","unstructured":"Liu L, Li Y, Chen G, Chen QJJ, o. B. S. (2023) Crosstalk between mitochondrial biogenesis and mitophagy to maintain mitochondrial homeostasis. J Biomed Sci 30(1):86","journal-title":"J Biomed Sci"},{"key":"4257_CR73","doi-asserted-by":"publisher","unstructured":"Liu W-Y, Zheng KI, Pan X-Y, Ma H-L, Zhu P-W, Wu X-X, . . . Zheng M-H (2020) Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. 35(6):1057\u20131064. https:\/\/doi.org\/10.1111\/jgh.14894","DOI":"10.1111\/jgh.14894"},{"issue":"1","key":"4257_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"J-K Long","year":"2019","unstructured":"Long J-K, Dai W, Zheng Y-W, Zhao S-P (2019) miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med 25(1):26. https:\/\/doi.org\/10.1186\/s10020-019-0085-2","journal-title":"Mol Med"},{"issue":"3","key":"4257_CR75","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK (2022) AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology 163(3):764-774.e761. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.023","journal-title":"Gastroenterology"},{"issue":"Suppl_3","key":"4257_CR76","doi-asserted-by":"publisher","first-page":"113164","DOI":"10.1161\/circ.142.suppl_3.13164","volume":"142","author":"F Luo","year":"2020","unstructured":"Luo F, Hobbs HH, Cohen JCJC (2020) Tm6sf2 is a regulator of liver fat metabolism in smooth ER influencing VLDL lipidation. Circulation 142(Suppl_3):113164\u2013113164","journal-title":"Circulation"},{"key":"4257_CR77","doi-asserted-by":"publisher","unstructured":"Luo F, Oldoni F, Das A (2022) TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease.\u00a0Hepatol Commun 6(3):448\u2013460. https:\/\/doi.org\/10.1002\/hep4.1822","DOI":"10.1002\/hep4.1822"},{"issue":"3","key":"4257_CR78","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.cmet.2018.01.005","volume":"27","author":"A Mardinoglu","year":"2018","unstructured":"Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A, R\u00e4s\u00e4nen SM, Bor\u00e9n J (2018) An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab 27(3):559-571.e555. https:\/\/doi.org\/10.1016\/j.cmet.2018.01.005","journal-title":"Cell Metab"},{"key":"4257_CR79","doi-asserted-by":"crossref","unstructured":"Meroni M, Longo M, Tria G, Dongiovanni P (2021) Genetics is of the essence to face NAFLD. 9(10):1359","DOI":"10.3390\/biomedicines9101359"},{"issue":"4","key":"4257_CR80","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5114\/aoms\/150639","volume":"19","author":"B Mitrovic","year":"2023","unstructured":"Mitrovic B, Gluvic ZM, Obradovic M, Radunovic M, Rizzo M, Banach M, Isenovic ER (2023) Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci 19(4):884\u2013894. https:\/\/doi.org\/10.5114\/aoms\/150639","journal-title":"Arch Med Sci"},{"key":"4257_CR81","doi-asserted-by":"crossref","unstructured":"Mocciaro G, George AL, Allison M, Frontini M, Huang\u2010Doran I, Reiman F, . . . Azzu VJLI (2025) Oxidised apolipoprotein peptidome characterises metabolic dysfunction\u2010associated steatotic liver disease. 45(2):e16200.","DOI":"10.1111\/liv.16200"},{"key":"4257_CR82","doi-asserted-by":"crossref","unstructured":"Mohs A, Otto T, Schneider KM, Peltzer M, Boekschoten M, Holland CH, . . . Saez-Rodriguez JJJoh (2021) Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis. 74(3):638\u2013648","DOI":"10.1016\/j.jhep.2020.09.037"},{"key":"4257_CR83","doi-asserted-by":"crossref","unstructured":"Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, . . . Ratziu VJJoH (2020) Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. 72(5):828\u2013838.","DOI":"10.1016\/j.jhep.2019.12.008"},{"key":"4257_CR84","doi-asserted-by":"publisher","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, . . . Doo E (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet 385(9972):956\u2013965. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"4257_CR85","doi-asserted-by":"crossref","unstructured":"Niederseer D, Wernly B, Aigner E, Stickel F, Datz CJJoCM (2021) NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations.\u00a0J Clin Med\u00a010(3):467","DOI":"10.3390\/jcm10030467"},{"key":"4257_CR86","doi-asserted-by":"crossref","unstructured":"Njei B, Al-Ajlouni YA, Ugwendum D, Abdu M, Forjindam A, Mohamed MFJTG, Hepatology (2023) Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review. 9:11","DOI":"10.21037\/tgh-23-31"},{"key":"4257_CR87","doi-asserted-by":"publisher","unstructured":"Omagari K, Suzuta M, Taniguchi A, Kumamoto R, Koyama Y, Fukuda A, . . . Tsuneyama K (2020) A non-obese, diet-induced animal model of nonalcoholic steatohepatitis in Wistar\/ST rats compared to Sprague-Dawley rats. Clin Nutr Exp 30:1\u201314. https:\/\/doi.org\/10.1016\/j.yclnex.2020.03.001","DOI":"10.1016\/j.yclnex.2020.03.001"},{"key":"4257_CR88","doi-asserted-by":"publisher","unstructured":"Ong SY, Khoo T, Nicoll AJ, Gurrin L, Worland T, Pateria P, . . . Delatycki MB (2021) Utility and limitations of hepascore and transient elastography to detect advanced hepatic fibrosis in HFE hemochromatosis. Sci Rep 11(1):14654. https:\/\/doi.org\/10.1038\/s41598-021-94083-x","DOI":"10.1038\/s41598-021-94083-x"},{"key":"4257_CR89","unstructured":"Patel AH, Peddu D, Amin S, Elsaid MI, Minacapelli CD, Chandler T-M, . . . Hepatology T (2023) Nonalcoholic fatty liver disease in lean\/nonobese and obese individuals: a comprehensive review on prevalence, pathogenesis, clinical outcomes, and treatment. 11(2):502"},{"key":"4257_CR90","doi-asserted-by":"crossref","unstructured":"Perkins HT, Allan VJ, Waigh TAJSR (2021) Network organisation and the dynamics of tubules in the endoplasmic reticulum. 11(1):16230","DOI":"10.1038\/s41598-021-94901-2"},{"key":"4257_CR91","doi-asserted-by":"crossref","unstructured":"Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, . . . Caldwell SJG (2016) Elafibranor, an agonist of the peroxisome proliferator\u2212 activated receptor\u2212 \u03b1 and\u2212 \u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. 150(5):1147\u20131159. e1145.","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"4257_CR92","doi-asserted-by":"publisher","unstructured":"Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, . . . Ratziu V (2022) Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 76(3):536\u2013548. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029","DOI":"10.1016\/j.jhep.2021.10.029"},{"key":"4257_CR93","first-page":"1452696","volume":"1","author":"S Rius-P\u00e9rez","year":"2020","unstructured":"Rius-P\u00e9rez S, Torres-Cuevas I, Mill\u00e1n I, Ortega \u00c1L (2020) P\u00e9rez SJ Om, longevity c (2020) PGC-1\u03b1, inflammation, and oxidative stress: an integrative view in metabolism. Oxidative Med Cell Longev 1:1452696","journal-title":"Oxidative Med Cell Longev"},{"issue":"2","key":"4257_CR94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","volume":"68","author":"PK Santhekadur","year":"2018","unstructured":"Santhekadur PK, Kumar DP, Sanyal AJ (2018) Preclinical models of non-alcoholic fatty liver disease. J Hepatol 68(2):230\u2013237. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.031","journal-title":"J Hepatol"},{"issue":"3","key":"4257_CR95","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4254\/wjh.v16.i3.452","volume":"16","author":"K Sato-Espinoza","year":"2024","unstructured":"Sato-Espinoza K, Chotiprasidhi P, Huaman MR, D\u00edaz-Ferrer J (2024) Update in lean metabolic dysfunction-associated steatotic liver disease. World J Hepatol 16(3):452\u2013464. https:\/\/doi.org\/10.4254\/wjh.v16.i3.452","journal-title":"World J Hepatol"},{"key":"4257_CR96","doi-asserted-by":"publisher","first-page":"c5702","DOI":"10.1136\/bmj.c5702","volume":"341","author":"M Sch\u00fcrks","year":"2010","unstructured":"Sch\u00fcrks M, Glynn RJ, Rist PM, Tzourio C, Kurth T (2010) Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 341:c5702. https:\/\/doi.org\/10.1136\/bmj.c5702","journal-title":"BMJ"},{"key":"4257_CR97","doi-asserted-by":"crossref","unstructured":"Shen N, Tang L, Qian Y, Pan J, Pan J, Miao H, . . . Xing LJAoTM (2023) Serum miR-4488 as a potential biomarker of lean nonalcoholic fatty liver disease. 11(4):73","DOI":"10.21037\/atm-22-6620"},{"key":"4257_CR98","doi-asserted-by":"publisher","unstructured":"Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, . . . Lavine JE (2023) Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. J Hepatol 78(2):238\u2013246. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.027","DOI":"10.1016\/j.jhep.2022.10.027"},{"key":"4257_CR99","doi-asserted-by":"crossref","unstructured":"Skat\u2010R\u00f8rdam J, H\u00f8jland Ipsen D, Lykkesfeldt J, Tveden\u2010Nyborg PJB, pharmacology c, toxicology (2019) A role of peroxisome proliferator\u2010activated receptor \u03b3 in non\u2010alcoholic fatty liver disease. 124(5), 528\u2013537","DOI":"10.1111\/bcpt.13190"},{"issue":"5","key":"4257_CR100","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","volume":"61","author":"S Softic","year":"2016","unstructured":"Softic S, Cohen DE, Kahn CR (2016) Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 61(5):1282\u20131293. https:\/\/doi.org\/10.1007\/s10620-016-4054-0","journal-title":"Dig Dis Sci"},{"issue":"8","key":"4257_CR101","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41366-019-0363-7","volume":"43","author":"JR Speakman","year":"2019","unstructured":"Speakman JR (2019) Use of high-fat diets to study rodent obesity as a model of human obesity. Int J Obes (Lond) 43(8):1491\u20131492. https:\/\/doi.org\/10.1038\/s41366-019-0363-7","journal-title":"Int J Obes (Lond)"},{"key":"4257_CR102","doi-asserted-by":"crossref","unstructured":"Sulaiman SA, Dorairaj V, Adrus MNH (2023) Genetic polymorphisms and diversity in nonalcoholic fatty liver disease (NAFLD): a mini review. 11(1):106","DOI":"10.3390\/biomedicines11010106"},{"key":"4257_CR103","doi-asserted-by":"publisher","unstructured":"Sun Q-F, Tang L-J, Wang M-J, Zhu P-W, Li Y-Y, Ma H-L, . . . Zheng M-H (2022) Potential blood DNA methylation biomarker genes for diagnosis of liver fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. 9. https:\/\/doi.org\/10.3389\/fmed.2022.864570","DOI":"10.3389\/fmed.2022.864570"},{"key":"4257_CR104","doi-asserted-by":"crossref","unstructured":"Sun B, Ding X, Tan J, Zhang J, Chu X, Zhang S, . . . Hepatology M (2024) TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD. 30(4):863","DOI":"10.3350\/cmh.2024.0268"},{"key":"4257_CR105","doi-asserted-by":"crossref","unstructured":"Tacke F, Weiskirchen RJAoTM (2021)\u00a0Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med 9(8):729","DOI":"10.21037\/atm-20-4354"},{"issue":"19","key":"4257_CR106","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","volume":"18","author":"Y Takahashi","year":"2012","unstructured":"Takahashi Y, Soejima Y, Fukusato T (2012) Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol 18(19):2300\u20132308. https:\/\/doi.org\/10.3748\/wjg.v18.i19.2300","journal-title":"World J Gastroenterol"},{"key":"4257_CR107","doi-asserted-by":"publisher","first-page":"870239","DOI":"10.3389\/fimmu.2022.870239","volume":"13","author":"S-P Tang","year":"2022","unstructured":"Tang S-P, Mao X-L, Chen Y-H, Yan L-L, Ye L-P, Li S-WJFII (2022) Reactive oxygen species induce fatty liver and ischemia-reperfusion injury by promoting inflammation and cell death. Front Immunol 13:870239","journal-title":"Front Immunol"},{"key":"4257_CR108","doi-asserted-by":"publisher","unstructured":"Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, . . . Subramanian P (2021) Loss of hepatic Mboat7 leads to liver fibrosis. Gut 70(5):940\u2013950. https:\/\/doi.org\/10.1136\/gutjnl-2020-320853","DOI":"10.1136\/gutjnl-2020-320853"},{"key":"4257_CR109","doi-asserted-by":"publisher","unstructured":"T\u00f8lb\u00f8l KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, . . . Feigh M (2018) Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 24(2):179\u2013194. https:\/\/doi.org\/10.3748\/wjg.v24.i2.179","DOI":"10.3748\/wjg.v24.i2.179"},{"key":"4257_CR110","doi-asserted-by":"publisher","unstructured":"T\u00f8lb\u00f8l KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Sch\u00f6nberger T, . . . Broermann A (2019) Disease progression and pharmacological intervention in a nutrient-deficient rat model of nonalcoholic steatohepatitis. Dig Dis Sci 64(5):1238\u20131256. https:\/\/doi.org\/10.1007\/s10620-018-5395-7","DOI":"10.1007\/s10620-018-5395-7"},{"issue":"6","key":"4257_CR111","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2613.2011.00793.x","volume":"92","author":"V Trak-Smayra","year":"2011","unstructured":"Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B (2011) Pathology of the liver in obese and diabetic ob\/ob and db\/db mice fed a standard or high-calorie diet. Int J Exp Pathol 92(6):413\u2013421. https:\/\/doi.org\/10.1111\/j.1365-2613.2011.00793.x","journal-title":"Int J Exp Pathol"},{"key":"4257_CR112","doi-asserted-by":"publisher","unstructured":"Vali Y, Lee J, Boursier J, Spijker R, L\u00f6ffler J, Verheij J, . . . Zwinderman K (2020) Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 73(2):252\u2013262. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.036","DOI":"10.1016\/j.jhep.2020.03.036"},{"key":"4257_CR113","doi-asserted-by":"crossref","unstructured":"Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, . . . medicine LSRTJJoc (2021) FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. 10(11):2415","DOI":"10.3390\/jcm10112415"},{"key":"4257_CR114","doi-asserted-by":"crossref","unstructured":"Van Dijk A-M, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, . . . Bossuyt PMJJocm (2021) Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease. 10(13):2910","DOI":"10.3390\/jcm10132910"},{"key":"4257_CR115","doi-asserted-by":"publisher","unstructured":"Veskovi\u0107 M, Pejovi\u0107 M, \u0160utulovi\u0107 N, Hrn\u010di\u0107 D, Ra\u0161i\u0107-Markovi\u0107 A, Stanojlovi\u0107 O, Mladenovi\u0107 D (2024) Exploring fibrosis pathophysiology in lean and obese metabolic-associated fatty liver disease: an in-depth comparison. Int J Mol Sci 25(13). https:\/\/doi.org\/10.3390\/ijms25137405","DOI":"10.3390\/ijms25137405"},{"key":"4257_CR116","doi-asserted-by":"publisher","unstructured":"Vilimova M, Contrant M, Randrianjafy R, Dumas P, Elbasani E, Ojala P\u00e4ivi M, . . . Fender A (2021) Cis regulation within a cluster of viral microRNAs. Nucleic Acids Res 49(17):10018\u201310033. https:\/\/doi.org\/10.1093\/nar\/gkab731","DOI":"10.1093\/nar\/gkab731"},{"issue":"2","key":"4257_CR117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/1573399810666140508121012","volume":"10","author":"B Wang","year":"2014","unstructured":"Wang B, Chandrasekera PC, Pippin JJ (2014) Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. Curr Diabetes Rev 10(2):131\u2013145. https:\/\/doi.org\/10.2174\/1573399810666140508121012","journal-title":"Curr Diabetes Rev"},{"key":"4257_CR118","doi-asserted-by":"crossref","unstructured":"Wei S, Nguyen TT, Zhang Y, Ryu D, Gariani KJFie (2023) Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management.\u00a0Front Endocrinol\u00a014:1185221","DOI":"10.3389\/fendo.2023.1185221"},{"key":"4257_CR119","doi-asserted-by":"crossref","unstructured":"Williams KB, Horst M, Young M, Pascua C, Puffenberger EG, Brigatti KW, . . . Strauss KAJBCD (2022) Clinical characterization of familial hypercholesterolemia due to an Amish founder mutation in Apolipoprotein B. 22(1):109","DOI":"10.1186\/s12872-022-02539-3"},{"key":"4257_CR120","doi-asserted-by":"publisher","unstructured":"Xin F-Z, Zhao,Z-H, Liu X-L, Pan Q, Wang Z-X, Zeng L, . . . Fan J-G (2022) <em>Escherichia fergusonii<\/em> Promotes nonobese nonalcoholic fatty liver disease by interfering with host hepatic lipid metabolism through its own msRNA 23487. Cell Mol Gastroenterol Hepatol 13(3):827\u2013841. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.12.003","DOI":"10.1016\/j.jcmgh.2021.12.003"},{"key":"4257_CR121","doi-asserted-by":"publisher","unstructured":"Xiong Y, Shi X, Xiong X, Li S, Zhao H, Song H, . . . Wu N (2024) A systematic review and meta-analysis of randomized controlled trials: effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD. Food Funct 15(16):8248\u20138257. https:\/\/doi.org\/10.1039\/d4fo01461h","DOI":"10.1039\/d4fo01461h"},{"key":"4257_CR122","doi-asserted-by":"publisher","first-page":"113331","DOI":"10.1016\/j.biopha.2022.113331","volume":"153","author":"R Xu","year":"2022","unstructured":"Xu R, Pan J, Zhou W, Ji G, Dang Y (2022) Recent advances in lean NAFLD. Biomed Pharmacother 153:113331. https:\/\/doi.org\/10.1016\/j.biopha.2022.113331","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4257_CR123","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4093\/dmj.2022.0048","volume":"46","author":"X-L Zhang","year":"2022","unstructured":"Zhang X-L, Wang T-Y, Targher G, Byrne CD, Zheng M-H (2022) Lifestyle Interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J 46(3):391\u2013401. https:\/\/doi.org\/10.4093\/dmj.2022.0048","journal-title":"Diabetes Metab J"},{"key":"4257_CR124","doi-asserted-by":"publisher","first-page":"1247611","DOI":"10.3389\/fendo.2023.1247611","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Ji G, Li MJFiE, (2023) Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD. Front Endocrinol 14:1247611","journal-title":"Front Endocrinol"},{"key":"4257_CR125","doi-asserted-by":"crossref","unstructured":"Zhang L, Wang X, Cueto R, Effi C, Zhang Y, Tan H, . . . Wang HJ Rb (2019) Biochemical basis and metabolic interplay of redox regulation. 26:101284","DOI":"10.1016\/j.redox.2019.101284"},{"key":"4257_CR126","doi-asserted-by":"publisher","unstructured":"Zhang E, Zhao Y, Hu H (2021) Impact of sodium glucose cotransporter 2 inhibitors on nonalcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Commun 5(5):736\u2013748. https:\/\/doi.org\/10.1002\/hep4.1611","DOI":"10.1002\/hep4.1611"},{"key":"4257_CR127","doi-asserted-by":"crossref","unstructured":"Zhou J, Zheng Q, Chen ZJFIC, Biology D (2022a) The Nrf2 pathway in liver diseases. Front Cell Dev Biol 10:826204","DOI":"10.3389\/fcell.2022.826204"},{"key":"4257_CR128","doi-asserted-by":"crossref","unstructured":"Zhou Y, Long D, Zhao Y, Li S, Liang Y, Wan L, Zhang J, Xue F, Feng L (2022b) Oxidative stress-mediated mitochondrial fission promotes hepatic stellate cell activation via stimulating oxidative phosphorylation. Cell Death Dis 13(8):689","DOI":"10.1038\/s41419-022-05088-x"},{"key":"4257_CR129","doi-asserted-by":"publisher","unstructured":"Zhu X, Huang Q, Ma S, Chen L, Wu Q, Wu L, . . . Xia M (2023) Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people. Hepatol Int 17(2):313\u2013325. https:\/\/doi.org\/10.1007\/s12072-022-10439-z","DOI":"10.1007\/s12072-022-10439-z"},{"issue":"20","key":"4257_CR130","doi-asserted-by":"publisher","first-page":"11128","DOI":"10.3390\/ijms222011128","volume":"22","author":"S Ziolkowska","year":"2021","unstructured":"Ziolkowska S, Binienda A, Jab\u0142kowski M, Szemraj J, Czarny PJIJOMS (2021) The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease. Int J Mol 22(20):11128","journal-title":"Int J Mol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04257-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04257-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:11:36Z","timestamp":1759983096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04257-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":130,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4257"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04257-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"AI technology is not used during manuscript writing (except for checking grammar and spelling).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}